VKTX — Viking Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $8.49bn
- $7.52bn
- 62
- 28
- 82
- 58
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 32.7 | 42.7 | 55.7 | 70.4 | 101 |
Operating Profit | -32.7 | -42.7 | -55.7 | -70.4 | -101 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -25.8 | -39.5 | -55 | -68.9 | -85.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -25.8 | -39.5 | -55 | -68.9 | -85.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -25.8 | -39.5 | -55 | -68.9 | -85.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -25.8 | -39.5 | -55 | -68.9 | -85.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.358 | -0.544 | -0.712 | -0.896 | -0.91 |